Copy
View this email in your browser
COVID-19 vaccine development: challenges and solutions
COVID-19 crisis is dramatically displaying the need to expedite vaccine development in order to mitigate national, regional and global uncertainties and fear. The need for effective vaccine in shortest timeframe possible is leading to the rise of novel and different vaccine strategies, some of them based on nucleic acids, produced in cell cultures or just following strategies in gene therapy. Hand in hand, this situation and its dimension call for the most innovative and productive bioprocessing tools available.
BIA Separations' monoliths are tailored to address swift process development and commercial manufacturing needs of COVID-19 Vaccine candidates, such as:

- pDNA
- mRNA
- VLP
- Viral Vectors
- Enveloped and Non-Enveloped Viruses

Visit our COVID-19 dedicated webpage and learn more about our solutions.
Removal of host cell DNA is essential for all human-injectable biologics. This poster shows a method for achieving low host cell levels in preparations of exosomes. Purified exosome samples were prepared with anion exchange chromatography (AEC) and pre-treated with tangential flow filtration (TFF) and nuclease treatment. Results are compared with an experimental control using TFF and size exclusion chromatography (SEC).
*The poster was prepared for the purposes of the ISBioTech 10th Spring Meeting conference, which was unfortunately cancelled.
The growth of BIA Separations' expansion
Finally, the decision has been made!
9th Monolith Summer Symposium will be held next year in Portorož, from June 14th through the 18th.

If you have not registred yet, click on the button below :) 
We are looking forward to your presence.
Register here
Facebook
Twitter
Website
LinkedIn
Copyright © 2020 BIA Separations, All rights reserved.


Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

Email Marketing Powered by Mailchimp